Procedure code and description
72148 – MRI lumbar spine w/o dye – average fee payment – $230 – $240
72141 – Mri neck spine w/o dye – average fee payment – $230 – $240
72156 Syringomyelia (Syrinx) Myelopthy Discitis (disk infection) Multiple Sclerosis (MS) Osteomyelitis
MRI SPINE Lumbar
MRI Lumbar Spine without contrast 72148 Back/leg pain Sciatica/radiculopathy Degenerative disk disease Spondylolisthesis Disk herniation (HNP) Spinal stenosis Radiculopathy Compression fracture Trauma Scoliosis No Neurology
MRI Lumbar Spine with and without contrast 72158 Discitis (disk infection) Post-op hx of back surgery Osteomyelitis Tumor/Mass/Cancer/Mets Yes Neurology
MRI – 72148
MR Lumbar without contrast
• Disc bulges
• Disc herniation
• Incontinence
• Low back pain
• Radiculopathy
• Spinal stenosis
• Trauma
MR Lumbar without contrast with Flexion & Extension
• Back pain/lower extremity radicular symptoms, especially when position dependent .
• Back pain/lower extremity radicular symptoms w/ suspected low back instability
• Disc bulge
• Disc herniation
• Incontinence
• Spinal stenosis
• Trauma
Magnetic Resonance Imaging (MRI) is used to diagnose a variety of central nervous system disorders. Unlike computed tomography (CT) scanning, MRI does not make use of ionizing radiation or require iodinated contrast material (known for causing hypersensitivity reactions and nephrotoxicity in susceptible patients) to distinguish normal from pathologic tissue. Rather, the difference in the number of protons contained within hydrogen-rich molecules in the body (water, proteins, lipids, and other macromolecules) determines recorded image qualities and makes possible the distinction of spinal cord from intra- vertebral disc, tumor from normal tissue, and flowing blood within vascular structures.
MRI is able to image in multiple planes, a distinct advantage in the diagnosis of spinal cord and vertebral column anomalies. MRI is also superior to myelography, a riskier, more uncomfortable, and less informative procedure than MRI.
- Evaluation of the spine in patients with infections of the brain, spinal column or contiguous areas or those having systemic infection.
- Detection and characterization of neoplastic processes that may affect the spine, either primary or secondary.
- Characterization of endocrine or other systemic diseases that may affect the spine.
- Assessing injury or spinal sequelae after trauma or surgery. In individuals with certain systemic diseases, the trauma need not be major to cause injury. Minor trauma (e.g., nursing home falls) often does not result in cervical spine fractures or other significant injury. Imaging may be unnecessary when reliable historical information regarding the traumatic event/injury and physical examination (e.g. patients who are fully/awake and alert, no sensory deficit, no distracting pain, etc.) have ruled out significant cervical spine injury. Imaging is generally appropriate in the absence of reliable history and/or physical information, or when examination cannot exclude the possibility of significant injury of the spine or spinal contents.
- For assessment of prolonged pain, pain with neurological manifestations or with an unusual presentation of pain.
- For assessing certain arthritides with spine manifestations.
- For assessing certain neurologic disorders.
- For assessing congenital disorders that may affect the spine.
- For further characterizing an abnormality detected on another imaging exam.
- Intramedullary tumors of spinal cord.
- Suspected spinal infections.
- Syringomyelia/syringohydromyelia.
- Cord infarction.
- Vertebral fractures.
- Radiation myelitis.
- Postoperative spine evaluation.
- Developmental abnormalities.
- Spinal cord compression.
- Radiculopathy.
- Demyelination or inflammation.
- Metastatic/neoplastic disease of the spine.
- Discitis and vertebral osteomyelitis.
- Spinal cord trauma.
- Spinal stenosis (CT may occasionally be preferred to MRI for evaluating spinal stenosis).
- Fractures.
- Arthritis.
- Bone neoplasms.
- When performed in conjunction with contrast myelography.
- Reasonable and medically necessary for the individual patient.
- Performed on a unit that has received federal Food and Drug Administration (FDA) approval. Such a unit(s) must be operated within the parameters specified by that approval.
- Reasonable and medically necessary for the individual patient.
- Performed on a model of CT equipment that meets specific Medicare criteria.
Contractors shall consider a service to be reasonable and necessary if the contractor determines that the service is:
- Safe and effective.
- Not experimental or investigational (exception: routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000, which meet the requirements of the clinical trials NCD are considered reasonable and necessary).
- Appropriate, including the duration and frequency that is considered appropriate for the service, in terms of whether it is:
- Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient’s condition or to improve the function of a malformed body member.
- Furnished in a setting appropriate to the patient’s medical needs and condition.
- Ordered and furnished by qualified personnel.
- One that meets, but does not exceed, the patient’s medical need.
- At least as beneficial as an existing and available medically appropriate alternative.
The MRI is not covered when the following patient-specific contraindications are present:
• MRI is not covered for patients with cardiac pacemakers or with metallic clips on vascular aneurysms unless the Medicare beneficiary meets the provisions of the following exceptions:
Effective for claims with dates of service on or after July 7, 2011, the contraindications will not apply to pacemakers when used according to the FDA-approved labeling in an MRI environment, or effective for claims with dates of service on or after February 24, 2011, CMS believes that the evidence is promising although not yet convincing that MRI will improve patient health outcomes if certain safeguards are in place to ensure that the exposure of the device to an MRI environment adversely affects neither the interpretation of the MRI result nor the proper functioning of the implanted device itself. We believe that specific precautions (as listed below) could maximize benefits of MRI exposure for beneficiaries enrolled in clinical trials designed to assess the utility and safety of MRI exposure. Therefore, CMS determines that MRI will be covered by Medicare when provided in a clinical study under section 1862(a)(1)(E) (consistent with section 1142 of the Act) through the Coverage with Study Participation (CSP) form of Coverage with Evidence Development (CED) if the study meets the criteria in each of the three paragraphs in CMS Pub 100-03, CMS National Coverage Determination Manual, Chapter 1, Section 220.2.C.1.
• MRI during a viable pregnancy is also contraindicated at this time.
• The danger inherent in bringing ferromagnetic materials within range of MRI units generally constrains the use of MRI on acutely ill patients requiring life support systems and monitoring devices that employ ferromagnetic materials.
• In addition, the long imaging time and the enclosed position of the patient may result in claustrophobia, making patients who have a history of claustrophobia unsuitable candidates for MRI procedures.
Nationally Non-Covered Indications:
CMS has determined that MRI of cortical bone and calcifications, and procedures involving spatial resolution of bone and calcifications, are not considered reasonable and necessary indications within the meaning of section 1862(a)(1)(A) of the Act, and are therefore non-covered.
Bill Type Codes
CPT/HCPCS Codes
Note:
Providers are reminded to refer to the long descriptors of the CPT codes in their CPT book. The American Medical Association (AMA) and the Centers for Medicare & Medicaid Services (CMS) require the use of short CPT descriptors in policies published on the Web.
72125© Ct neck spine w/o dye
72126© Ct neck spine w/dye
72127© Ct neck spine w/o&w dye
72128© Ct chest spine w/o dye
72129© Ct chest spine w/dye
72130© Ct chest spine w/o&w dye
72131© Ct lumbar spine w/o dye
72132© Ct lumbar spine w/dye
72133© Ct lumbar spine w/o&w dye
72141© Mri neck spine w/o dye
72142© Mri neck spine w/dye
72146© Mri chest spine w/o dye
72147© Mri chest spine w/dye
72148© Mri lumbar spine w/o dye
72149© Mri lumbar spine w/dye
72156© Mri neck spine w/o&w dye
72157© Mri chest spine w/o&w dye
72158© Mri lumbar spine w/o&w dye
76380© Cat scan follow-up study
Numerator Statement:
Number of Lumbar MRI studies where there are indications in the claim file of antecedent conservative therapy among patients with low back pain (excluding operative, tumor, and acute injury cases). Antecedent conservative therapy may include codes for injectable analgesic care, manual therapy or massage, chiropractic care, or a prior exam for low back pain evaluation.
72148 – MRI Lumbar Spine without Contrast;
72149 – MRI Lumbar Spine with Contrast;
72158 – MRI Lumbar Spine With and Without Contrast
003.21
|
Salmonella meningitis
|
013.00–013.06
|
Tuberculous meningitis
|
013.10–013.16
|
Tuberculoma of meninges
|
013.20–013.26
|
Tuberculoma of brain
|
013.30–013.36
|
Tuberculous abscess of brain
|
013.40–013.46
|
Tuberculoma of spinal cord
|
013.50–013.56
|
Tuberculous abscess of spinal cord
|
013.60–013.66
|
Tuberculous encephalitis or myelitis
|
015.00–015.06
|
Tuberculosis of vertebral column
|
045.00–045.03
|
Acute paralytic poliomyelitis specified as bulbar
|
045.10–045.13
|
Acute poliomyelitis with other paralysis
|
045.20–045.23
|
Acute non-paralytic poliomyelitis
|
045.90–045.93
|
Acute poliomyelitis, unspecified
|
091.81
|
Acute syphilitic meningitis (secondary)
|
094.0–094.3
|
Neurosyphilis
|
094.81–094.87
|
Other specified neurosyphilis
|
094.89
|
Other specified neurosyphilis, other
|
094.9
|
Neurosyphilis, unspecified
|
098.82
|
Gonococcal meningitis
|
100.81
|
Leptospiral meningitis (aseptic)
|
112.83
|
Candidal meningitis
|
114.2
|
Coccidioidal meningitis
|
115.01
|
Histoplasma capsulatum meningitis
|
115.11
|
Histoplasma duboisii meningitis
|
130.0
|
Meningoencephalitis due to toxoplasmosis
|
140.0–140.1
|
Malignant neoplasm of lip
|
140.3–140.6
|
Malignant neoplasm of lip
|
140.8–140.9
|
Malignant neoplasm of lip
|
141.0–141.6
|
Malignant neoplasm of tongue
|
141.8–141.9
|
Malignant neoplasm of tongue
|
142.0–142.2
|
Malignant neoplasm of major salivary glands
|
142.8–142.9
|
Malignant neoplasm of major salivary glands
|
143.0–143.1
|
Malignant neoplasm of gum
|
143.8–143.9
|
Malignant neoplasm of gum
|
144.0–144.1
|
Malignant neoplasm of floor of mouth
|
144.8–144.9
|
Malignant neoplasm of floor of mouth
|
145.0–145.6
|
Malignant neoplasm of other and unspecified parts of mouth
|
145.8–145.9
|
Malignant neoplasm of other and unspecified parts of mouth
|
146.0–146.9
|
Malignant neoplasm of oropharynx
|
147.0–147.3
|
Malignant neoplasm of nasopharynx
|
147.8–147.9
|
Malignant neoplasm of nasopharynx
|
148.0–148.3
|
Malignant neoplasm of hypopharynx
|
148.8–148.9
|
Malignant neoplasm of hypopharynx
|
149.0–149.1
|
Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx
|
149.8–149.9
|
Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx
|
150.0–150.5
|
Malignant neoplasm of esophagus
|
150.8–150.9
|
Malignant neoplasm of esophagus
|
151.0–151.6
|
Malignant neoplasm of stomach
|
151.8–151.9
|
Malignant neoplasm of stomach
|
152.0–152.3
|
Malignant neoplasm of small intestine, including duodenum
|
152.8–152.9
|
Malignant neoplasm of small intestine, including duodenum
|
153.0–153.9
|
Malignant neoplasm of colon
|
154.0–154.3
|
Malignant neoplasm of rectum, rectosigmoid junction, and anus
|
154.8
|
Malignant neoplasm of anus unspecified
|
155.0–155.2
|
Malignant neoplasm of liver and intrahepatic bile ducts
|
156.0–156.2
|
Malignant neoplasm of gallbladder and extrahepatic bile ducts
|
156.8–156.9
|
Malignant neoplasm of gallbladder and extrahepatic bile ducts
|
157.0–157.4
|
Malignant neoplasm of pancreas
|
157.8–157.9
|
Malignant neoplasm of pancreas
|
158.0
|
Malignant neoplasm of retroperitoneum
|
158.8
|
Malignant neoplasm of specified parts of peritoneum
|
159.0–159.1
|
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum
|
159.8–159.9
|
Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum
|
160.0–160.5
|
Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses
|
160.8–160.9
|
Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses
|
161.0–161.3
|
Malignant neoplasm of larynx
|
161.8–161.9
|
Malignant neoplasm of larynx
|
162.0
|
Malignant neoplasm of trachea
|
162.2–162.5
|
Malignant neoplasm of trachea, bronchus, and lung
|
162.8–162.9
|
Malignant neoplasm of trachea, bronchus, and lung
|
163.0–163.1
|
Malignant neoplasm of pleura
|
163.8–163.9
|
Malignant neoplasm of pleura
|
164.0–164.3
|
Malignant neoplasm of thymus, heart, and mediastinum
|
164.8–164.9
|
Malignant neoplasm of thymus, heart, and mediastinum
|
165.0
|
Malignant neoplasm of upper respiratory tract, part unspecified
|
165.8–165.9
|
Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs
|
170.0–170.9
|
Malignant neoplasm of bone and articular cartilage
|
171.0
|
Malignant neoplasm of connective and other soft tissue, head, face and neck
|
171.2–171.9
|
Malignant neoplasm of connective and other soft tissue
|
172.0–172.9
|
Malignant melanoma of skin
|
173.0–173.9
|
Other malignant neoplasm of skin
|
174.0–174.6
|
Malignant neoplasm of female breast
|
174.8–174.9
|
Malignant neoplasm of female breast
|
175.0
|
Malignant neoplasm of male breast, nipple and areola
|
175.9
|
Malignant neoplasm of other and unspecified sites of male breast
|
176.0–176.5
|
Kaposi’s sarcoma
|
176.8–176.9
|
Kaposi’s sarcoma
|
179
|
Malignant neoplasm of uterus, part unspecified
|
180.0–180.1
|
Malignant neoplasm of cervix uteri
|
180.8–180.9
|
Malignant neoplasm of cervix uteri
|
181
|
Malignant neoplasm of placenta
|
182.0–182.1
|
Malignant neoplasm of body of uterus
|
182.8
|
Malignant neoplasm of other specified site of body of uterus
|
183.0
|
Malignant neoplasm of ovary
|
183.2–183.5
|
Malignant neoplasm of ovary and other uterine adnexa
|
183.8–183.9
|
Malignant neoplasm of ovary and other uterine adnexa
|
184.0–184.4
|
Malignant neoplasm of other and unspecified female genital organs
|
184.8–184.9
|
Malignant neoplasm of other and unspecified female genital organs
|
185
|
Malignant neoplasm of prostate
|
186.0
|
Malignant neoplasm of undescended testis
|
186.9
|
Malignant neoplasm of other and unspecified testis
|
187.1–187.9
|
Malignant neoplasm of penis and other male genital organs
|
188.0–188.9
|
Malignant neoplasm of bladder
|
189.0–189.4
|
Malignant neoplasm of kidney and other and unspecified urinary organs
|
189.8–189.9
|
Malignant neoplasm of kidney and other and unspecified urinary organs
|
190.0–190.9
|
Malignant neoplasm of eye
|
192.1–192.3
|
Malignant neoplasm of cerebral meninges, spinal cord, and spinal meninges
|
193
|
Malignant neoplasm of thyroid gland
|
194.6
|
Malignant neoplasm of aortic body and other paraganglia
|
195.0–195.5
|
Malignant neoplasm of other and ill-defined sites
|
195.8
|
Malignant neoplasm of other specified sites
|
196.0–196.3
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
196.5–196.6
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
196.8–196.9
|
Secondary and unspecified malignant neoplasm of lymph nodes
|
197.0–197.8
|
Secondary malignant neoplasm of respiratory and digestive systems
|
198.0*–198.7*
|
Secondary malignant neoplasm of other specified sites
|
198.81*–198.82*
|
Secondary malignant neoplasm of other specified sites
|
198.89*
|
Secondary malignant neoplasm of other specified sites
|
|
Note: Use 198.XX range of codes to indicate metastases to the spinal column.
|
199.0–199.2
|
Malignant neoplasm without specification of site
|
200.00–200.08
|
Reticulosarcoma
|
200.10–200.18
|
Lymphosarcoma
|
200.20–200.28
|
Burkitt’s tumor or lymphoma
|
200.30–200.38
|
Marginal zone lymphoma
|
200.40–200.48
|
Mantle cell lymphoma
|
200.50–200.58
|
Primary central nervous system lymphoma
|
200.60–200.68
|
Anaplastic large cell lymphoma
|
200.70–200.78
|
Large cell lymphoma
|
200.80–200.88
|
Lymphosarcoma and reticulosarcoma, other named variants
|
201.00–201.08
|
Hodgkin’s paragranuloma
|
201.10–201.18
|
Hodgkin’s granuloma
|
201.20–201.28
|
Hodgkin’s sarcoma
|
201.40–201.48
|
Hodgkin’s disease, lymphocytic-histiocytic predominance
|
201.50–201.58
|
Hodgkin’s disease, nodular sclerosis
|
201.60–201.68
|
Hodgkin’s disease, mixed cellularity
|
201.70–201.78
|
Hodgkin’s disease, lymphocytic depletion
|
201.90–201.98
|
Hodgkin’s disease, unspecified
|
202.00–202.08
|
Nodular lymphoma
|
202.10–202.18
|
Mycosis fungoides
|
202.20–202.28
|
Sezary’s disease
|
202.30–202.38
|
Malignant histiocytosis
|
202.40–202.48
|
Leukemic reticuloendotheliosis
|
202.50–202.58
|
Letterer-Siwe disease
|
202.60–202.68
|
Malignant mast cell tumors
|
202.70–202.78
|
Peripheral T cell lymphoma
|
202.80–202.88
|
Other lymphomas
|
202.90–202.98
|
Other and unspecified malignant neoplasms of lymphoid and histocytic tissue
|
203.00–203.02
|
Multiple myeloma
|
203.10–203.12
|
Plasma cell leukemia
|
203.80–203.82
|
Other immunoproliferative neoplasms
|
204.00–204.02
|
Acute lymphoid leukemia
|
204.10–204.12
|
Chronic lymphoid leukemia
|
204.20–204.22
|
Subacute lymphoid leukemia
|
204.80–204.82
|
Other lymphoid leukemia
|
204.90–204.92
|
Unspecified lymphoid leukemia
|
205.00–205.02
|
Acute myeloid leukemia
|
205.10–205.12
|
Chronic myeloid leukemia
|
205.20–205.22
|
Subacute myeloid leukemia
|
205.30–205.32
|
Myeloid sarcoma
|
205.80–205.82
|
Other myeloid leukemia
|
205.90–205.92
|
Unspecified myeloid leukemia
|
206.00–206.02
|
Acute monocytic leukemia
|
206.10–206.12
|
Chronic monocytic leukemia
|
206.20–206.22
|
Subacute monocytic leukemia
|
206.80–206.82
|
Other monocytic leukemia
|
206.90–206.92
|
Unspecified monocytic leukemia
|
207.00–207.02
|
Acute erythremia and erythroleukemia
|
207.10–207.12
|
Chronic erythremia
|
207.20–207.22
|
Megakaryocytic leukemia
|
207.80–207.82
|
Other specified leukemia
|
208.00–208.02
|
Acute leukemia of unspecified cell type
|
208.10–208.12
|
Chronic leukemia of unspecified cell type
|
208.20–208.22
|
Subacute leukemia of unspecified cell type
|
208.80–208.82
|
Other leukemia of unspecified cell type
|
208.90–208.92
|
Unspecified leukemia of unspecified cell type
|
213.2
|
Benign neoplasm of vertebral column, excluding sacrum and coccyx
|
213.9
|
Benign neoplasm of bone and articular cartilage, site unspecified
|
215.8–215.9
|
Other benign neoplasm of connective and other soft tissue
|
225.3–225.4
|
Benign neoplasm of brain and other parts of nervous system
|
225.8–225.9
|
Benign neoplasm of brain and other parts of nervous system
|
227.6
|
Benign neoplasm of aortic body and other paraganglia
|
228.00
|
Hemangioma of unspecified site
|
228.09
|
Hemangioma of other sites
|
237.5–237.6
|
Neoplasm of uncertain behavior of endocrine glands and nervous system
|
237.70–237.73
|
Neurofibromatosis
|
237.79
|
Other neurofibromatosis
|
237.9
|
Neoplasm of uncertain behavior of other and unspecified parts of nervous system
|
238.0–238.1
|
Neoplasm of uncertain behavior of other and unspecified sites and tissues
|
238.6
|
Neoplasm of uncertain behavior of plasma cells
|
238.72–238.75
|
Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues
|
239.2
|
Neoplasm of unspecified nature of bone, soft tissue, and skin
|
239.6–239.7
|
Neoplasm of unspecified nature
|
239.89
|
Neoplasms of unspecified nature, other specified sites
|
320.0–320.3
|
Bacterial meningitis
|
320.7
|
Meningitis in other bacterial diseases classified elsewhere
|
320.81
|
Meningitis due to other specified bacteria
|
320.89
|
Meningitis due to other specified bacteria
|
320.9
|
Meningitis due to unspecified bacterium
|
321.0–321.4
|
Meningitis due to other organisms
|
321.8
|
Meningitis due to other non-bacterial organisms classified elsewhere
|
322.0–322.2
|
Meningitis of unspecified cause
|
322.9
|
Meningitis, unspecified
|
323.01–323.02
|
Encephalitis, myelitis, and encephalomyelitis in viral diseases, classified elsewhere
|
323.1–323.2
|
Encephalitis, myelitis, and encephalomyelitis
|
323.41–323.42
|
Other encephalitis, myelitis, and encephalomyelitis due to infection, classified elsewhere
|
323.52
|
Myelitis following immunization procedures
|
323.61–323.63
|
Postinfectious encephalitis, myelitis, and encephalomyelitis
|
323.71–323.72
|
Toxic encephalitis and encephalomyelitis – Toxic myelitis
|
323.81–323.82
|
Other causes of encephalitis, myelitis, and encephalomyelitis
|
323.9
|
Unspecified cause of encephalitis
|
324.1
|
Intraspinal abscess
|
326
|
Late effects of intracranial abscess or pyogenic infection
|
335.20–335.24
|
Motor neuron disease
|
335.29
|
Other motor neuron diseases
|
336.0–336.3
|
Other diseases of spinal cord
|
336.8–336.9
|
Other diseases of spinal cord
|
340
|
Multiple sclerosis
|
341.0–341.1
|
Other demyelinating diseases of central nervous system
|
341.8–341.9
|
Other demyelinating diseases of central nervous system
|
343.0–343.4
|
Infantile cerebral palsy
|
343.8–343.9
|
Infantile cerebral palsy
|
344.00–344.04
|
Other paralytic syndromes
|
344.09
|
Other quadriplegia
|
344.1–344.2
|
Other paralytic syndromes
|
344.89
|
Other specified paralytic syndrome
|
349.1–349.2
|
Other and unspecified disorders of the nervous system
|
349.31
|
Accidental puncture or laceration of dura during a procedure
|
349.39
|
Other dural tear
|
353.2
|
Cervical root lesions, not elsewhere classified
|
354.4
|
Causalgia of upper limb
|
442.89*
|
Aneurysm of other specified site
|
|
Note: Use 442.89 to indicate aneurysm of spinal artery.
|
714.0
|
Rheumatoid arthritis
|
714.30
|
Chronic or unspecified polyarticular juvenile rheumatoid arthritis
|
720.0
|
Ankylosing spondylitis
|
720.81
|
Inflammatory spondylopathies in diseases classified elsewhere
|
721.1
|
Cervical spondylosis with myelopathy
|
721.91
|
Spondylosis of unspecified site with myelopathy
|
722.0
|
Displacement of cervical intervertebral disc without myelopathy
|
722.2
|
Displacement of intervertebral disc, site unspecified, without myelopathy
|
722.4
|
Degeneration of cervical intervertebral disc
|
722.71
|
Intervertebral disc disorder with myelopathy, cervical region
|
722.81
|
Postlaminectomy syndrome of cervical region
|
722.91
|
Other and unspecified disc disorder of cervical region
|
723.0
|
Spinal stenosis in cervical region
|
723.4
|
Brachial neuritis or radiculitis NOS
|
724.00
|
Spinal stenosis of unspecified region
|
730.08
|
Acute osteomyelitis involving other specified sites
|
730.18
|
Chronic osteomyelitis involving other specified sites
|
732.0
|
Juvenile osteochondrosis of spine
|
733.00–733.03
|
Other disorders of bone and cartilage, osteoporosis
|
733.09
|
Other disorders of bone and cartilage
|
733.10–733.16
|
Other disorders of bone and cartilage, pathologic fracture
|
733.19
|
Pathologic fracture of other specified site
|
733.20–733.22
|
Other disorders of bone and cartilage, cyst of bone
|
733.29
|
Other bone cyst
|
733.3
|
Hyperostosis of skull
|
733.40–733.44
|
Other disorders of bone and cartilage, aseptic necrosis of bone
|
733.49
|
Aseptic necrosis of other bone sites
|
733.5–733.7
|
Other disorders of bone and cartilage
|
733.81–733.82
|
Malunion and non-union of fracture
|
733.90–733.92
|
Disorder of bone and cartilage, unspecified
|
733.99
|
Other disorders of bone and cartilage, other
|
737.0
|
Adolescent postural kyphosis
|
737.10–737.12
|
Curvature of spine, kyphosis (acquired)
|
737.19
|
Other kyphosis, (acquired) (postural)
|
737.20–737.22
|
Curvature of spine, lordosis (acquired)
|
737.29
|
Other lordosis, acquired
|
737.30–737.34
|
Curvature of spine, kyphoscoliosis and scoliosis
|
737.39
|
Other kyphoscoliosis and scoliosis
|
737.40–737.43
|
Curvature of spine associated with other conditions
|
737.8*–737.9*
|
Curvature of spine
|
|
Note: Use 737.8 or 737.9 to indicate patients with clinically significant symptoms or for preoperative evaluation.
|
738.4
|
Acquired spondylolisthesis
|
741.00–741.01
|
Spina bifida, with hydrocephalus
|
741.90–741.91
|
Spina bifida, without mention of hydrocephalus
|
742.51
|
Diastematomyelia
|
742.53
|
Hydromyelia
|
742.59
|
Other specified congenital anomalies of spinal cord
|
742.9
|
Unspecified congenital anomaly of brain, spinal cord, and nervous system
|
747.82
|
Spinal vessel anomaly
|
754.2
|
Congenital musculoskeletal deformities of spine
|
756.12
|
Spondylolisthesis, congenital
|
756.4
|
Chondrodystrophy
|
758.0
|
Down’s syndrome
|
767.4
|
Injury to spine and spinal cord due to birth trauma
|
781.2
|
Abnormality of gait
|
781.4
|
Transient paralysis of limb
|
782.0
|
Symptom, disturbance of skin sensation
|
793.7*
|
Non-specific (abnormal) findings on radiological and other examination of musculoskeletal system
|
|
Note: Use 793.7 to indicate an abnormal bone scan.
|
793.91
|
Image test inconclusive due to excess body fat
|
793.99
|
Other nonspecific (abnormal) findings on radiological and other examination of body structure
|
805.00–805.08
|
Fracture of vertebral column without mention of spinal cord injury, cervical, closed
|
805.10–805.18
|
Fracture of vertebral column without mention of spinal cord injury, cervical, open
|
805.8–805.9
|
Fracture of vertebral column without mention of spinal cord injury
|
806.00–806.09
|
Fracture of vertebral column with spinal cord injury, cervical, closed
|
806.10–806.19
|
Fracture of vertebral column with spinal cord injury, cervical, open
|
806.8–806.9
|
Fracture of vertebral column with spinal cord injury
|
839.00–839.08
|
Other, multiple, and ill-defined dislocations, cervical vertebra, closed
|
839.10–839.18
|
Other, multiple, and ill-defined dislocations, cervical vertebra, open
|
839.49
|
Closed dislocation, other vertebra, other
|
839.59
|
Open dislocation, other vertebra, other
|
847.0
|
Neck Sprain
|
909.2
|
Late effect of radiation
|
925.2
|
Crushing injury of neck
|
926.11
|
Crushing injury of back
|
952.00–952.09
|
Spinal cord injury without evidence of spinal bone injury, cervical
|
952.8–952.9
|
Spinal cord injury without evidence of spinal bone injury
|
953.0
|
Injury to cervical nerve root
|
959.01*
|
Head injury, unspecified
|
|
Note: Use 959.01 to indicate possible injury, in tandem with supporting notes in chart.
|
959.09*
|
Injury of face and neck
|
|
Note: Use 959.09 to indicate possible injury, in tandem with supporting notes in chart.
|